Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton…

Original post: 
Algeta Announces First US Patient Randomized In ALSYMPCA Phase III Study At Tulane Cancer Center, New Orleans

Related posts:

1. Celsion Announces Treatment Of First Patient In China In Global Phase III ThermoDox(R) Trial For Primary Liver CancerCelsion Corporation, a leading oncology drug development company, announced today that the first patient in China has been enrolled and treated as part of Celsion's global Phase III ThermoDox HEAT...
2. Tulane Cancer Center To Begin Novel Clinical Trial For Late-Stage Prostate Cancer DrugInternational prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer...
3. Pacira Announces Results Of Another Positive Phase III Trial In Post Operative PainPacira Pharmaceuticals, Inc., announced that its second Phase III placebo controlled study of EXPAREL(TM) (DepoBupivacaine) met its primary endpoint... ...
4. Santarus Announces Completion Of Enrollment In European Phase III Clinical Trial For Budesonide MMXSantarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that its collaboration partner, Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA (SIX: COPN), has completed enrollment of 514...
5. Boehringer Ingelheim Initiates First Phase III Clinical Trial In Ovarian CancerBoehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced...
6. Degarelix (FIRMAGON(R)) Vs Leuprolide (Lupron Depot(R)) In Patients With Advanced Prostate Cancer: Further Analysis From A Phase III Pivotal TrialDrs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III...
7. Lorus Therapeutics Announces Positive Result In Its Phase II Clinical Study Of LOR-2040 In Acute Myeloid Leukemia (AML)Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announced that its...
8. Merck KGaA Starts Stimuvax Phase III Study INSPIRE In Asian Patients With Advanced NSCLCMerck KGaA announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer...
9. Adeona Announces Publication Of Results Of 160 Patient Phase 2 Clinical Trial Of Oral DnaJP1 For Rheumatoid ArthritisAdeona Pharmaceuticals, Inc. (AMEX: AEN) announced the publication in the journal Arthritis & Rheumatism of results of a 160-patient, six-month, double-blind, placebo-controlled Phase 2 clinical trial using the company's oral...
10. Ipsen Initiates An Advanced Endometrial Cancer Program With BN83495, Its First-in-Class Steroid Sulfatase Inhibitor First Patient Dosed In Phase IIIpsen (Paris:IPN) announced the initiation of an international, multi-center, controlled, randomized Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational first-in-class steroid sulfatase (STS) inhibitor,...
11. Agennix AG Announces Positive Results With Talactoferrin In Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial In Severe SepsisAgennix AG (FRANKFURT: AGX) (XETRA: AGX) reported results from the talactoferrin randomized, double-blind, placebo-controlled Phase 2 trial in severe sepsis. The trial evaluated talactoferrin versus placebo in 190 adult patients...
12. Second Pivotal Phase III Study Of Gilead’s Darusentan For Resistant Hypertension Misses Primary EndpointsGilead Sciences, Inc. (Nasdaq:GILD) announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve...
13. AEterna Zentaris Announces Positive Results For Phase 2 Study With LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 In Endometrial CancerAEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, announced positive efficacy data from a Phase 2 study with its...
14. Spectrum Pharmaceuticals Announces Completion Of Enrollment In One Apaziquone Phase 3 Pivotal Trial For Bladder Cancer Ahead Of ScheduleSpectrum Pharmaceuticals (NasdaqGM: SPPI) today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive...
15. The Medicines Company’s Full Analysis Of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patient Outcomes Following PCIThe Medicines Company (NASDAQ: MDCO) announced the data from 13,941 patients treated in the discontinued CHAMPION Phase III program of cangrelor. ...